Cardiovascular Status of Childhood Cancer Survivors Exposed and Unexposed to Cardiotoxic Therapy
Why the study?
Do childhood cancer survivors, regardless of exposure to cardiotoxic therapy, have increased cardiovascular abnormalities and atherosclerotic risk compared to sibling controls?
Population
201 survivors of childhood cancer at a median of 11 years after diagnosis and 76 sibling controls.
Comparison
Childhood cancer survivorship vs Sibling controls
Design
Cohort
Follow-up
median of 11 years after diagnosis (range, 3 to 32 years)
Authors
Discussion
Loading...
Member takes
Implication
Survivors warrant closer CV surveillance regardless of exposure; leaves open mechanisms and optimal screening strategies.
Structured PICO
Do childhood cancer survivors, regardless of exposure to cardiotoxic therapy, have increased cardiovascular abnormalities and atherosclerotic risk compared to sibling controls?
P
Population
201 survivors of childhood cancer (156 exposed to cardiotoxic treatments, 45 unexposed) at a median of 11 years after diagnosis (range, 3 to 32 years) and 76 sibling controls.
I
Intervention
Childhood cancer survivorship (exposed to cardiotoxic anthracyclines and cardiac irradiation, and unexposed)
C
Comparator
Sibling controls
O
Outcome
Echocardiographic characteristics and atherosclerotic disease risk (including NT-proBNP, non-HDL cholesterol, insulin, hs-CRP, and 30-year risk of myocardial infarction, stroke, or coronary death)surrogate
Childhood cancer survivors, even those unexposed to cardiotoxic therapies, exhibit cardiovascular abnormalities, systemic inflammation, and increased atherosclerotic risk compared to siblings.
Cite This Study
Lipshultz et al. (2012) studied this question.